3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
36
Neoplasm Metastasis
12
Neoplasms
10
Colorectal Neoplasms
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Multiple Myeloma
4
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Thyroid Carcinoma, Anaplastic
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Brain Neoplasms
2
Thyroid cancer, follicular
1
Thrombocytosis
1
Sarcoma, Clear Cell
1
Sarcoma
1
Relapsed Pediatric Solid Tumor
1
Rare Tumour
1
Rare Tumor
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
cobimetinib
2
trametinib
1
temsirolimus
1
dabrafenib
1
Vemurafenib
1
Valproic Acid
1
Specimen Handling
1
Sirolimus
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Biopsy
1
Bevacizumab
1
68Ga-pentixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Erdheim-Chester Disease
×
Vemurafenib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled